Mounjaro 0.5 mg: what does this dose actually do?

Why do people search for Mounjaro 0.5 mg when it doesn't exist?

It is an easy mix-up. When a prescriber talks you through your injection, they will often say something like "draw to the 0.5 ml mark" or "each dose is 0.5 ml." That volume figure lodges in people's minds, and it reads like a strength. Searching for "0.5 mounjaro" or "0.5 ml of Mounjaro" is sensible, you are trying to understand what you have been prescribed.

The clarification matters, though. Mounjaro's UK licence covers six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Every single one is injected as 0.5 ml of solution. The concentration of tirzepatide in that 0.5 ml changes with each strength; the volume does not. So the pen for a patient on 15 mg looks physically similar to the one used at 2.5 mg, the difference is inside it.

If a seller, website or social-media account offers you a "Mounjaro 0.5 mg" pen, treat that as a red flag, since it suggests the product is mislabelled, counterfeit, or simply doesn't exist. The MHRA's Yellow Card scheme allows anyone to report suspect sellers of medicines, and the MHRA has repeatedly warned about fake weight-loss pens circulating online. Genuine Mounjaro is sourced through the licensed UK supply chain and arrives from a GPhC-registered pharmacy, not via a social media listing.

What is the 2.5 mg starting dose actually for?

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, which together slow how quickly the stomach empties and reduce appetite. Those effects, while beneficial for weight management, can produce nausea, stomach discomfort or loose stools, particularly when the body first encounters the medicine. The NHS's tirzepatide guidance notes that gastrointestinal side effects are among the most commonly reported, and they tend to be more noticeable after starting treatment or after each dose increase.

The 2.5 mg dose is there to give your system time to adjust. It is not expected to produce large weight changes on its own, its job is to establish tolerability before the prescriber moves you up the schedule. Most people stay at 2.5 mg for around four weeks. After that, the prescriber assesses how you have tolerated it and whether it is clinically appropriate to increase. The increases follow a set schedule through 5, 7.5, 10, 12.5 and 15 mg, but the timing and endpoint are always the prescriber's call, not the patient's.

The SURMOUNT-1 clinical trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% over 72 weeks at the 15 mg maintenance dose. That outcome was reached through the full titration schedule, not at the starting point. Understanding that the early doses are a runway, not the destination, helps set realistic expectations from the first pen.

What does the actual pen look like at the 2.5 mg dose?

Mounjaro comes in a KwikPen format, a pre-filled, pre-set device. There is nothing to draw up or measure. You select an injection site (abdomen, thigh or upper arm, rotating each week), attach a needle, and the pen delivers 0.5 ml automatically. A cap and a dose counter confirm what you have used. The pen itself is compact enough to store in a fridge door shelf, though exact storage and any limited room-temperature window are set out in the Patient Information Leaflet, the Mounjaro SmPC on the eMC is the definitive reference for those details.

When Mounjaro is dispensed through a regulated UK pharmacy like nume, the pen arrives via tracked DPD delivery in plain, unbranded packaging, no indication on the outside of what is inside. You can follow the parcel in real time on your phone. Each box contains one pen, covering four weeks of weekly injections at whichever strength you have been prescribed.

If you are considering treatment for the first time and want to understand the full range of strengths, our guide to Mounjaro strengths covers the complete UK schedule. For a closer look at how the 2.5 mg pen itself is specified, the Mounjaro 2.5 mg / 0.5 ml pen page has the detail. Costs vary across the dose schedule, and our cost context page explains what is typically included in a private prescription price.

Who can be prescribed Mounjaro in the UK?

Mounjaro's UK licence covers adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, for example, high blood pressure, prediabetes, high cholesterol or obstructive sleep apnoea. NICE's technology appraisal (TA1026) sets NHS eligibility at BMI 35 or above with at least one qualifying comorbidity, with the phased NHS rollout meaning criteria are currently strict. Lower BMI thresholds of 2.5 kg/m² apply for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds, in line with UK clinical guidance.

Private prescribing follows the licensed criteria, but eligibility is never confirmed by BMI alone. A prescriber weighs the whole picture: your medical history, any contraindications, current medicines, and your goals. Conditions like a personal or family history of medullary thyroid carcinoma, pregnancy, and certain gastrointestinal disorders may affect suitability. Mounjaro is not licensed for use in under-18s.

For a broader overview of how tirzepatide is licensed and used in the UK, our Mounjaro pillar page is a good place to start. If you are weighing it against the next dose step, the 5 mg information page explains what typically changes after the initial titration. Questions about whether you might be suitable are best answered directly, check your eligibility through a free consultation, reviewed the same day by a GPhC-registered prescriber.